This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Niguldipine
Accession Number
DB09239
Type
Small Molecule
Groups
Experimental
Description

Niguldipine is a calcium channel blocker and a1-adrenergic receptor antagonist.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Niguldipine hydrochloride1G8C7QS9SR113145-69-0MHOSUIMBPQVOEU-WAQYZQTGSA-N
Categories
UNII
Z81N45O25Z
CAS number
113165-32-5
Weight
Average: 609.723
Monoisotopic: 609.283885988
Chemical Formula
C36H39N3O6
InChI Key
SVJMLYUFVDMUHP-XIFFEERXSA-N
InChI
InChI=1S/C36H39N3O6/c1-25-31(34(40)44-3)33(27-12-10-17-30(24-27)39(42)43)32(26(2)37-25)35(41)45-23-11-20-38-21-18-36(19-22-38,28-13-6-4-7-14-28)29-15-8-5-9-16-29/h4-10,12-17,24,33,37H,11,18-23H2,1-3H3/t33-/m0/s1
IUPAC Name
3-[3-(4,4-diphenylpiperidin-1-yl)propyl] 5-methyl (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
[H]N1C(C)=C([[email protected]](C2=CC(=CC=C2)[N+]([O-])=O)C(C(=O)OCCCN2CCC(CC2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1C)C(=O)OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Niguldipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Niguldipine.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Niguldipine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Niguldipine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Niguldipine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Niguldipine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Niguldipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Niguldipine.Approved, Withdrawn
AmbrisentanNiguldipine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNiguldipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Niguldipine.Approved
AmobarbitalThe metabolism of Niguldipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Niguldipine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Niguldipine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Niguldipine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Niguldipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Niguldipine.Approved
AtenololAtenolol may increase the hypotensive activities of Niguldipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Niguldipine is combined with Atosiban.Approved, Investigational
Atracurium besylateNiguldipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Niguldipine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Niguldipine.Experimental
BarbexacloneThe metabolism of Niguldipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Niguldipine can be increased when combined with Barbital.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Niguldipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Niguldipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Niguldipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Niguldipine.Approved
BepridilBepridil may increase the hypotensive activities of Niguldipine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Niguldipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Niguldipine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Niguldipine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Niguldipine.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Niguldipine.Approved
BosentanBosentan may increase the hypotensive activities of Niguldipine.Approved, Investigational
BQ-123Niguldipine may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Niguldipine.Experimental
BretyliumBretylium may increase the hypotensive activities of Niguldipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Niguldipine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Niguldipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Niguldipine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Niguldipine.Investigational
BupranololBupranolol may increase the hypotensive activities of Niguldipine.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Niguldipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Niguldipine.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Niguldipine.Experimental
CafedrineNiguldipine may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanNiguldipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Niguldipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Niguldipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Niguldipine.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Niguldipine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Niguldipine.Approved
CarbomycinThe metabolism of Niguldipine can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Niguldipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Niguldipine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Niguldipine.Approved, Investigational
CaseinThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Niguldipine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Niguldipine.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Niguldipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Niguldipine.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Niguldipine.Approved
CicletanineNiguldipine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Niguldipine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Niguldipine.Approved
CimetidineThe serum concentration of Niguldipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Niguldipine can be decreased when combined with Clarithromycin.Approved
ClonidineClonidine may increase the hypotensive activities of Niguldipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Niguldipine.Approved, Nutraceutical
CloranololNiguldipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Niguldipine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Niguldipine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Niguldipine.Approved
CyclopenthiazideNiguldipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Niguldipine.Approved
CymarinCymarin may decrease the cardiotoxic activities of Niguldipine.Experimental
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Niguldipine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Niguldipine.Approved, Investigational
DelaprilNiguldipine may increase the hypotensive activities of Delapril.Experimental
DeserpidineNiguldipine may increase the hypotensive activities of Deserpidine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Niguldipine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Niguldipine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Niguldipine.Vet Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Niguldipine.Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Niguldipine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Niguldipine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Niguldipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Niguldipine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Niguldipine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Niguldipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Niguldipine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Niguldipine.Approved
EfavirenzThe serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Niguldipine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
EnalaprilatNiguldipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Niguldipine.Experimental
EpanololNiguldipine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Niguldipine.Approved
EprosartanEprosartan may increase the hypotensive activities of Niguldipine.Approved
ErythromycinThe metabolism of Niguldipine can be decreased when combined with Erythromycin.Approved, Vet Approved
FelodipineFelodipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Niguldipine.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Niguldipine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Niguldipine.Experimental
FluconazoleThe serum concentration of Niguldipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Niguldipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Niguldipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Fluvastatin.Approved
FosinoprilFosinopril may increase the hypotensive activities of Niguldipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Niguldipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Niguldipine.Approved, Investigational, Vet Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Niguldipine.Experimental
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Niguldipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Niguldipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Niguldipine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Niguldipine.Approved
GuanazodineNiguldipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Niguldipine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Niguldipine.Approved, Investigational
GuanoclorNiguldipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNiguldipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNiguldipine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Niguldipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Niguldipine.Approved, Withdrawn
HarmalineHarmaline may increase the hypotensive activities of Niguldipine.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of Niguldipine.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Niguldipine.Approved, Investigational
HexobarbitalThe metabolism of Niguldipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Niguldipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Niguldipine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Niguldipine.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
ImidaprilNiguldipine may increase the hypotensive activities of Imidapril.Investigational
IndapamideIndapamide may increase the hypotensive activities of Niguldipine.Approved
IndenololIndenolol may increase the hypotensive activities of Niguldipine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Niguldipine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Niguldipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Niguldipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Niguldipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Niguldipine.Approved
IsradipineIsradipine may increase the hypotensive activities of Niguldipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Niguldipine.Approved, Investigational
JosamycinThe metabolism of Niguldipine can be decreased when combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Niguldipine.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Niguldipine.Approved, Investigational
KitasamycinThe metabolism of Niguldipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Niguldipine.Approved
LacidipineLacidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Niguldipine.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Niguldipine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
LinsidomineNiguldipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Niguldipine.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Niguldipine.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Niguldipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Lovastatin.Approved, Investigational
MacitentanNiguldipine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Niguldipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Niguldipine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Niguldipine.Experimental
MethohexitalThe metabolism of Niguldipine can be increased when combined with Methohexital.Approved
MethoserpidineNiguldipine may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Niguldipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Niguldipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Niguldipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Niguldipine can be increased when combined with Methylphenobarbital.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Niguldipine.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Niguldipine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Niguldipine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Niguldipine.Approved, Investigational
MetyrosineNiguldipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Niguldipine.Experimental
MibefradilMibefradil may increase the hypotensive activities of Niguldipine.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Niguldipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Niguldipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Niguldipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Niguldipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Niguldipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Niguldipine.Investigational
MivacuriumNiguldipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Niguldipine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Niguldipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Niguldipine.Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Niguldipine.Approved, Investigational
MuzolimineNiguldipine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Niguldipine.Experimental
NadololNadolol may increase the hypotensive activities of Niguldipine.Approved
NafcillinThe metabolism of Niguldipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Niguldipine.Approved
NaftopidilNiguldipine may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Niguldipine.Approved
NebivololNebivolol may increase the hypotensive activities of Niguldipine.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Niguldipine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Niguldipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Niguldipine.Approved, Investigational
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Niguldipine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Niguldipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Niguldipine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Niguldipine.Approved, Investigational
NitroprussideNiguldipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Niguldipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Niguldipine.Approved, Vet Approved
ObinutuzumabNiguldipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Niguldipine.Withdrawn
OleandomycinThe metabolism of Niguldipine can be decreased when combined with Oleandomycin.Vet Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Niguldipine.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Niguldipine.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Niguldipine.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Niguldipine.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Niguldipine.Approved
OxprenololOxprenolol may increase the hypotensive activities of Niguldipine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Niguldipine.Investigational
PargylinePargyline may increase the hypotensive activities of Niguldipine.Approved
PenbutololPenbutolol may increase the hypotensive activities of Niguldipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Niguldipine.Approved
PentobarbitalThe metabolism of Niguldipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Niguldipine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Niguldipine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Niguldipine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Niguldipine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Niguldipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Niguldipine.Withdrawn
PhenobarbitalThe metabolism of Niguldipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Niguldipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Niguldipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Niguldipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Niguldipine.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Niguldipine.Withdrawn
PindololPindolol may increase the hypotensive activities of Niguldipine.Approved
PirlindolePirlindole may increase the hypotensive activities of Niguldipine.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Niguldipine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Niguldipine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Niguldipine.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Niguldipine.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Niguldipine.Approved
PrimidoneThe metabolism of Niguldipine can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Niguldipine.Approved
PropranololPropranolol may increase the hypotensive activities of Niguldipine.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Niguldipine.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Niguldipine.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Niguldipine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Niguldipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Niguldipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Niguldipine.Approved
RapacuroniumNiguldipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Niguldipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Niguldipine.Approved
RescinnamineNiguldipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Niguldipine.Approved, Investigational
RifabutinThe serum concentration of Niguldipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Niguldipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Niguldipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Niguldipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Niguldipine.Investigational
RiociguatNiguldipine may increase the hypotensive activities of Riociguat.Approved
RituximabNiguldipine may increase the hypotensive activities of Rituximab.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Rosuvastatin.Approved
SafrazineSafrazine may increase the hypotensive activities of Niguldipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Niguldipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Niguldipine.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Niguldipine.Experimental
SecobarbitalThe metabolism of Niguldipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Niguldipine.Approved, Investigational, Vet Approved
SelexipagNiguldipine may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Niguldipine.Approved
SildenafilSildenafil may increase the antihypertensive activities of Niguldipine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Niguldipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Niguldipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Niguldipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Niguldipine.Approved, Investigational
SitaxentanNiguldipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe metabolism of Niguldipine can be decreased when combined with Solithromycin.Investigational
SpiraprilSpirapril may increase the hypotensive activities of Niguldipine.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Niguldipine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Niguldipine.Approved, Investigational
TalinololNiguldipine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Niguldipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Niguldipine.Approved
TelithromycinThe metabolism of Niguldipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Niguldipine.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Niguldipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Niguldipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Niguldipine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Niguldipine.Approved, Investigational
TetrahydropalmatineNiguldipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineNiguldipine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Niguldipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Niguldipine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Niguldipine.Approved
TiboloneTibolone may increase the hypotensive activities of Niguldipine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Niguldipine.Withdrawn
TimololTimolol may increase the hypotensive activities of Niguldipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Niguldipine.Approved
TolazolineTolazoline may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Niguldipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Niguldipine.Approved, Vet Approved
TolonidineNiguldipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Niguldipine.Approved
TorasemideTorasemide may increase the hypotensive activities of Niguldipine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Niguldipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Niguldipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Niguldipine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Niguldipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Niguldipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Niguldipine.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Niguldipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Niguldipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Niguldipine.Approved, Investigational
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Niguldipine.Approved, Investigational
TylosinThe metabolism of Niguldipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Niguldipine is combined with Ubidecarenone.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Niguldipine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Niguldipine.Approved
UrapidilUrapidil may increase the hypotensive activities of Niguldipine.Investigational
ValsartanValsartan may increase the hypotensive activities of Niguldipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Niguldipine.Approved
VincamineNiguldipine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNiguldipine may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Niguldipine.Approved, Investigational
XipamideNiguldipine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Niguldipine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Niguldipine.Approved, Vet Approved
ZofenoprilNiguldipine may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. Boer R, Grassegger A, Schudt C, Glossmann H: (+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1989 May 11;172(2):131-45. [PubMed:2548881]
External Links
PubChem Compound
60602
PubChem Substance
310265142
ChemSpider
54630
BindingDB
50453799
ChEBI
103931
ChEMBL
CHEMBL405355
Wikipedia
Niguldipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000113 mg/mLALOGPS
logP6.27ALOGPS
logP5.6ChemAxon
logS-6.7ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)9.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.01 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity185.9 m3·mol-1ChemAxon
Polarizability66.15 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylpiperidines / Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives
show 10 more
Substituents
Diphenylmethane / Phenylpiperidine / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Nitroaromatic compound / Aralkylamine / Dihydropyridine / Piperidine / Hydropyridine / Dicarboxylic acid or derivatives
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249]

Drug created on October 23, 2015 11:02 / Updated on November 09, 2017 04:48